GSK, Vir partner on infectious diseases therapies

By The Science Advisory Board staff writers

February 17, 2021 -- GlaskoSmithKline (GSK) and Vir Biotechnology have signed a deal to research and develop new therapies for influenza and other respiratory viruses.

GSK has been granted the exclusive rights to collaborate with Vir on the development of potential monoclonal antibodies (mAbs) for the prevention or treatment of influenza. These include VIR-2482, an intramuscularly administered, investigational mAb, designed as a universal prophylactic for influenza A. GSK also will have the exclusive option to co-develop VIR-2482 after Vir completes and reports phase II trial outcomes, and it will share development costs on the development of all other influenza mAbs.

Additionally, they will collaborate to develop up to three neutralizing mAbs to target noninfluenza pathogens during a three-year research period.

This deal builds upon their 2020 agreement to research and develop therapies for coronaviruses. Under the agreement, GSK will make an upfront payment of $225 million and an equity investment in Vir of $120 million. If GSK exercises its option to co-develop VIR-2482 past phase II, it will pay an option fee of $300 million. GSK will also pay Vir up to $200 million based on the successful delivery of predefined regulatory milestones.

GSK, CureVac collaborate on next-gen multivalent mRNA COVID-19 vaccines
Glaxo Smith Kline (GSK) and CureVac have entered into a collaboration to jointly develop next-generation messenger RNA (mRNA) vaccines for COVID-19, with...
Vir, GSK begin trial for COVID-19 monoclonal antibody
Vir Biotechnology and GlaxoSmithKline (GSK) have dosed the first patient in a new subtrial of the U.S. National Institutes of Health's Accelerating COVID-19...
GSK licenses cancer immunotherapy from Surface Oncology
GlaxoSmithKline (GSK) has obtained an exclusive license worldwide and commercial rights to Surface Oncology's preclinical program, SRF813, an antitumor...
Sanofi, GSK COVID-19 vaccine program delayed by responses in elderly
Sanofi and GlaxoSmithKline (GSK) are delaying their adjuvanted recombinant protein-based COVID-19 vaccine program to improve the vaccine's immune response...
Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter